RT Journal Article
SR Electronic
T1 Targeted Sequencing of the 9p21.3 Region Reveals Association with Reduced Disease risks in Ashkenazi Jewish Centenarians
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.19.23290237
DO 10.1101/2023.05.19.23290237
A1 Zhu, Yizhou
A1 Ryu, Seungjin
A1 Tare, Archana
A1 Barzilai, Nir
A1 Atzmon, Gil
A1 Suh, Yousin
YR 2023
UL http://medrxiv.org/content/early/2023/05/23/2023.05.19.23290237.abstract
AB Genome-wide association studies (GWAS) have pinpointed the chromosomal locus 9p21.3 as a genetic hotspot for various age-related disorders. Common genetic variants in this locus are linked to multiple traits, including coronary artery diseases, cancers, and diabetes. Centenarians are known for their reduced risk and delayed onset of these conditions. To investigate whether this evasion of disease risks involves diminished genetic risks in the 9p21.3 locus, we sequenced this region in an Ashkenazi Jewish centenarian cohort (centenarians: n=450, healthy controls: n=500). Risk alleles associated with cancers, glaucoma, CAD, and T2D showed a significant depletion in centenarians. Furthermore, the risk- and non-risk genotypes are linked to two distinct low-frequency variant profiles, enriched in controls and centenarians, respectively. Our findings provide evidence that the extreme longevity cohort is associated with collectively lower risks of multiple age-related diseases in the 9p21.3 locus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the NIH grants AG017242, GM104459, and CA180126 (Suh).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee on Clinical Investigations of the Albert Einstein College of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.